These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12968816)

  • 1. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
    Fischer MA; Avorn J
    Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.
    Kelton CM; Chang LV; Kreling DH
    Health Aff (Millwood); 2013 Jul; 32(7):1204-11. PubMed ID: 23836735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicaid prescription limits: policy trends and comparative impact on utilization.
    Lieberman DA; Polinski JM; Choudhry NK; Avorn J; Fischer MA
    BMC Health Serv Res; 2016 Jan; 16():15. PubMed ID: 26772962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Private expenditures on brand name prescription drugs after generic entry.
    Balaban DY; Dhalla IA; Law MR; Bell CM
    Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State Medicaid pharmacy payments and their relation to estimated costs.
    Adams EK; Kreling DH; Gondek K
    Health Care Financ Rev; 1994; 15(3):25-42. PubMed ID: 10137796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can increases in CHIP copayments reduce program expenditures on prescription drugs?
    Sen B; Blackburn J; Morrisey M; Becker D; Kilgore M; Caldwell C; Menachemi N
    Medicare Medicaid Res Rev; 2014; 4(2):. PubMed ID: 24967148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic script share and the price of brand-name drugs: the role of consumer choice.
    Rizzo JA; Zeckhauser R
    Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicaid payment for generic drugs: achieving savings and access.
    Peters CP
    Issue Brief George Wash Univ Natl Health Policy Forum; 2010 Sep; (839):1-16. PubMed ID: 20928958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.